ARCADIA-CSI, (Cognition and Silent Infarcts)

Overview

About this study

The purpose of ARCADIA-CSI is to determine the effect of apixaban vs aspirin on these two additional outcomes in patients with stroke of unknown cause and atrial cardiopathy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Randomized in ARCADIA and on study drug.
Able to undergo magnetic resonance imaging (MRI).
Able to provide self-consent for ARCADIA-CSI in English (cognitive status and language ability sufficient to provide informed consent).
A score of 0 or 1 on language component of the NIHSS at time of ARCADIA-CSI enrollment.

Exclusion Criteria:

Diagnosis of dementia.
Known active illicit drug use.
Psychiatric admission or ECT for major depression within last two years.
Education less than 8 years.
History of traumatic brain injury with loss of consciousness of more than 30 minutes.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Jacksonville, Fla. Mayo Clinic principal investigator Michelle Lin, M.D., M.P.H.	Closed for enrollment

Mayo Clinic Location

Status

Jacksonville, Fla.

Mayo Clinic principal investigator

Michelle Lin, M.D., M.P.H.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials